1. Ukita, Masayo, Hamanishi, Junzo, Yoshitomi, Hiroyuki, Ueno, Hideki, Mandai, Masaki. 2022. CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. In JCI insight, 7, . doi:10.1172/jci.insight.157215. https://pubmed.ncbi.nlm.nih.gov/35552285/
2. Law, Calvin, Wacleche, Vanessa Sue, Cao, Ye, Choi, Jaehyuk, Rao, Deepak A. 2024. Interferon subverts an AHR-JUN axis to promote CXCL13+ T cells in lupus. In Nature, 631, 857-866. doi:10.1038/s41586-024-07627-2. https://pubmed.ncbi.nlm.nih.gov/38987586/
3. Hu, Chupeng, You, Wenhua, Kong, Deyuan, Kuang, Dong-Ming, Chen, Yun. 2023. Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13+CD103+CD8+ Tissue-Resident Memory T-Cell Response to Programmed Cell Death Protein 1 Blockade in Cancer Immunotherapy. In Gastroenterology, 166, 1069-1084. doi:10.1053/j.gastro.2023.10.022. https://pubmed.ncbi.nlm.nih.gov/38445519/
4. Hu, Xinyue, Ni, Songjia, Zhao, Kai, Qian, Jing, Duan, Yang. 2022. Bioinformatics-Led Discovery of Osteoarthritis Biomarkers and Inflammatory Infiltrates. In Frontiers in immunology, 13, 871008. doi:10.3389/fimmu.2022.871008. https://pubmed.ncbi.nlm.nih.gov/35734177/
5. Ma, Longfei, Yu, Lina, Jiang, Bao-Chun, Tao, Yuan-Xiang, Yan, Min. 2021. ZNF382 controls mouse neuropathic pain via silencer-based epigenetic inhibition of Cxcl13 in DRG neurons. In The Journal of experimental medicine, 218, . doi:10.1084/jem.20210920. https://pubmed.ncbi.nlm.nih.gov/34762123/
6. Cabrita, Rita, Lauss, Martin, Sanna, Adriana, Svane, Inge Marie, Jönsson, Göran. 2020. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. In Nature, 577, 561-565. doi:10.1038/s41586-019-1914-8. https://pubmed.ncbi.nlm.nih.gov/31942071/
7. Han, Dawoon, Lee, A Yeong, Kim, Taehee, Kim, Soo-Chan, Kim, Jong Hoon. 2023. Microenvironmental network of clonal CXCL13+CD4+ T cells and Tregs in pemphigus chronic blisters. In The Journal of clinical investigation, 133, . doi:10.1172/JCI166357. https://pubmed.ncbi.nlm.nih.gov/37815865/
8. Yang, Moran, Lu, Jiaqi, Zhang, Guodong, Xu, Congjian, Liu, Haiou. . CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. In Journal for immunotherapy of cancer, 9, . doi:10.1136/jitc-2020-001136. https://pubmed.ncbi.nlm.nih.gov/33452206/
9. Beider, Katia, Voevoda-Dimenshtein, Valeria, Zoabi, Ali, Peled, Amnon, Nagler, Arnon. 2022. CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression. In Journal of hematology & oncology, 15, 144. doi:10.1186/s13045-022-01366-5. https://pubmed.ncbi.nlm.nih.gov/36217194/
10. Wang, Jie, Yin, Chengyu, Pan, Yushuang, Fang, Jianqiao, Liu, Boyi. 2023. CXCL13 contributes to chronic pain of a mouse model of CRPS-I via CXCR5-mediated NF-κB activation and pro-inflammatory cytokine production in spinal cord dorsal horn. In Journal of neuroinflammation, 20, 109. doi:10.1186/s12974-023-02778-x. https://pubmed.ncbi.nlm.nih.gov/37158939/